|
Nef
|
nef
|
HIV-1 Nef induces release of TSG101 (MAL-dependent exosome marker) from Jurkat T cells transfected with DNA constructs coding for Nef-GFP |
PubMed
|
|
nef
|
HIV-1 Nef is detected in detergent-insoluble AChE+/CD81 low/TSG101 low exosomes, but not in detergent-soluble AChE-/CD81 high/TSG101 high exosomes in Nef-transfected 293T cells |
PubMed
|
|
nef
|
HIV-1 Nef associates with TSG101 in extracellular vesicles isolated from HIV-1-infected patients |
PubMed
|
|
Pr55(Gag)
|
gag
|
HIV-1 Gag incorporates PDCD6IP (ALIX) and TSG101 into virions |
PubMed
|
|
gag
|
Knockdown of TSG101 impairs terminal cleavage of p24/p2 to p24 |
PubMed
|
|
gag
|
Superresolution imaging of HIV-1 Gag and ESCRT proteins (TSG101, ALIX, CHMP4B, and CHMP4C) demonstrates in HeLa cells that Gag assemblages often has ESCRT proteins in their direct vicinity |
PubMed
|
|
gag
|
Three-dimensional superresolution microscopy and correlative electron microscopy demonstrate that the ESCRT proteins TSG101, CHMP2A, and CHMP4B co-cluster with membrane-localized HIV-1 Gag at assembly sites |
PubMed
|
|
gag
|
Tsg 101, VPS 28, and VPS 37B form the human endosomal sorting complex required for transport (ESCRT-I), which is required for HIV-1 Gag budding and virus infectivity |
PubMed
|
|
gag
|
Deletion of HIV-1 NC zinc-finger 2 motif in HIV-1 Gag impairs the recruitment of TSG101 at the plasma membrane and its incorporation into virions |
PubMed
|
|
gag
|
Released Gag VLPs contain TSG101 and CHMP4B, but reduced levels of CHMP2A relative to CHMP4B |
PubMed
|
|
gag
|
Fusion protein Dub-TSG101, the catalytic domain of the Herpes Simplex UL36 deubiquitinating enzyme (DUb) fused onto TSG101, inhibits HIV-1 release, which involes the interaction between HIV-1 Gag and TSG101 |
PubMed
|
|
gag
|
The interaction between HIV-1 Gag and TSG101 enhances tetherin recruitment in HeLa cells. Both TSG101 and ALIX binding sites within the p6 domain of Gag enhance tetherin recruitment to Gag assembly sites in T cells |
PubMed
|
|
gag
|
AIP1 binds to the LXXLF motif in HIV-1 p6 (amino acids 41-44) and also binds to TSG101 to act as a component of the viral budding machinery |
PubMed
|
|
gag
|
The direct binding of the UEV domain (amino acids 1-145) of TSG101 to the L domain (amino acids 7-10) of HIV-1 p6-Gag is essential for the p6 directed budding of HIV-1 virions from infected cells |
PubMed
|
|
gag
|
TSG101 binding to HIV-1 Gag correlates with redistribution of IP3R to the plasma membrane |
PubMed
|
|
gag
|
Tal, a Tsg101-associated ligase, binds and ubiquitylates Tsg101; Tal-mediated binding and ubiquitylation of Tsg101 cooperatively regulate release of HIV-1 Gag |
PubMed
|
|
gag
|
The p1 spacer peptide in HIV-1 Gag can confer a requirement for Tsg101 binding. Removal of NC-p1 region from authentic HIV-1 alleviates sensitivity to dominant-negative CHMP3 |
PubMed
|
|
gag
|
The PTAP sequence (179-182) in the GAT domain and the PSAP sequence (310-313) in the C-terminal region of Tom1L1 are required for its interaction with the UEV domain (1-145) of Tsg101 and competes with HIV-1 Gag |
PubMed
|
|
gag
|
Expression of HIV-1 Gag attenuates SDF-1-mediated downregulation of CXCR4. The effect of Gag is dependent on a TSG101 interacting motif within the C-terminal p6 region of Gag |
PubMed
|
|
gag
|
The Bro1 domain of Alix inhibits HIV budding by targeting both PTAP/TSG101 and LYPXnL/Alix pathways. The NC domain of Gag is the primary target for Bro1 inhibition by Gag-mediated recruitment of Bro1 to the plasma membrane |
PubMed
|
|
gag
|
A genetically selected cyclic peptide IYWNVSGW inhibits HIV budding by targeting the interaction between the p6 domain of Gag and TSG101. The inhibitory activity of the peptide is PT/SAP dependent |
PubMed
|
|
gag
|
The hydroxyl of the Thr or Ser residue in the P(S/T)AP motif of HIV-1 Gag forms hydrogen bonds with the main chain of Asn69. Mutation of the Asn to Pro abrogates PTAP motif binding to TSG101 and blocks budding of HIV-1 from cells |
PubMed
|
|
gag
|
The p6 domain of HIV-1 Gag mimics the Tsg101-recruiting activity of the human Hrs protein |
PubMed
|
|
Vpr
|
vpr
|
HIV-1 Vpr competes with TSG101 to bind Gag |
PubMed
|
|
vpr
|
HIV-1 Vpr abrogates the effect of TSG101 overexpression to support virus like particle release |
PubMed
|
|
Vpu
|
vpu
|
Physiological levels of Vpu requires the core ESCRT pathway (TSG1010 and UBAP1) and HGA (HRS) for Vpu-mediated BST-2 (tetherin) degradation but does not require these proteins for counteraction of BST2 (tetherin's) physical antiviral activity |
PubMed
|
|
capsid
|
gag
|
siRNA knockdown of TSG101 in U1/HIV-1 cells (chronically infected monocytoid cells harboring 2 integrated copies of HIV provirus per cell) affects (decreases) CA (p24) levels in supernatants but not intracellular CA (p24) levels |
PubMed
|
|
gag
|
Knockdown of TSG101 impairs terminal cleavage of p24/p2 to p24 |
PubMed
|
|
nucleocapsid
|
gag
|
Deletion of HIV-1 NC zinc-finger 2 motif in HIV-1 Gag impairs the recruitment of TSG101 at the plasma membrane (PM) and its incorporation into virions, suggesting NC-mediated recruitment of TSG101 to Gag assembly sites occur at the PM |
PubMed
|
|
p2
|
gag
|
A computational approach, based on structural similarity of 9 HIV-1 proteins to human proteins having known interactions, predicts that HIV-1 gp41, IN, and the p2 region of Gag may all be able to interact with TSG101 |
PubMed
|
|
gag
|
Knockdown of TSG101 impairs terminal cleavage of p24/p2 to p24 |
PubMed
|
|
p6
|
gag
|
The direct binding of the UEV domain (amino acids 1-145) of TSG101 to the L domain (amino acids 7-10) of HIV-1 p6-Gag is essential for the p6 directed budding of HIV-1 virions from infected cells |
PubMed
|
|
gag
|
AIP1 binds to the LXXLF motif in HIV-1 p6 (amino acids 41-44) and also binds to TSG101 to act as a component of the viral budding machinery |
PubMed
|
|
gag
|
ESCRT-I complexes contain three common subunits (TSG101, VPS28, and VPS37), and a fourth subunit MVB12. Recombinant ESCRT-I complexes bind HIV-1 p6 |
PubMed
|
|
gag
|
Employing N-alkylglycine ('peptoid') residues to the p6-derived 9-mer sequence 'PEPTAPPEE' improves peptide binding affinity to the ubiquitin E2 variant domain of TSG101 |
PubMed
|
|
gag
|
NEDD4L-mediated stimulation of virus budding is dependent upon the ubiquitin ligase activity of NEDD4L and requires only the minimal HIV-1 Gag assembly regions and TSG101 |
PubMed
|
|
gag
|
Expression of HIV-1 Gag attenuates SDF-1-mediated downregulation of CXCR4. This effect of Gag is dependent on a TSG101 interacting motif within the C-terminal p6 region of Gag |
PubMed
|
|
gag
|
A genetically selected cyclic peptide IYWNVSGW inhibits HIV budding by targeting the interaction between the p6 domain of Gag and TSG101. The inhibitory activity of the peptide is PT/SAP dependent |
PubMed
|
|
gag
|
The hydroxyl of the Thr or Ser residue in the P(S/T)AP motif of HIV-1 p6 forms hydrogen bonds with the main chain of Asn69. Mutation of the Asn to Pro abrogates PTAP motif binding to TSG101 and blocks budding of HIV-1 from cells |
PubMed
|
|
gag
|
The p6 domain of HIV-1 Gag mimics the Tsg101-recruiting activity of the human Hrs protein |
PubMed
|
|
gag
|
A short helix (helix-1; amino acid residues 14-18) in HIV-1 p6 enhances the binding of the p6 PTAP motif (residues 7-10) to TSG101 |
PubMed
|
|
reverse transcriptase
|
gag-pol
|
HIV-1 late RT activity is specifically increased by siRNA-mediated knockdown of TSG101 expression, showing that TSG101 inhibits HIV-1 from reverse transcribing its genome into DNA prior to virus release |
PubMed
|